ThomasHOpenshawMD

Oncology • Hyannis, MA

Medical Oncology Specialist Eastern Maine Medical Center. Houlton Regional Hospital, Sebasticook Valley Health, Millinocket Regional Hospital, Down East Community Hospital

Join to view full profile

Dr. Openshaw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Openshaw's full profile

Already have an account?

Office
27 Park St
Hyannis, MA 02601
Phone+1 508-862-7575

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Vanderbilt University Medical CenterResidency, Internal Medicine, 1982 - 1985
Albany Medical CollegeClass of 1982

Certifications & Licensure

MA State Medical License 2019 - 2026
ME State Medical License 1989 - 2021
CT State Medical License 1984 - 1988
TN State Medical License 1984 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

36 citations
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer ...
N. Lynn Henry, Mark R. Somerfield, Vandana G. Abramson, Nofisat Ismaila, Kimberly H. Allison
Journal of Clinical Oncology. 2019-06-17
61 citations
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorse...
N. Lynn Henry, Mark R. Somerfield, Vandana G. Abramson, Kimberly H. Allison, Carey K. Anders
Journal of Clinical Oncology. 2016-09-27
3 citations
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Otto Metzger Filho, Anita Giobbie-Hurder, Nan Lin, Meredith Faggen, Steven E. Come
Breast Cancer Research and Treatment. 2021-01-01